Biotech
Takeda Ends Denali Deal, Returns Dementia Drug in Strategic Reset
Takeda exits its partnership with Denali Therapeutics, returning dementia drug DNL593 as part of a major restructuring plan involving layoffs and cost optimization.
S
Surya Pratap Singh
4/7/2026, 6:45:58 AM
